Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.
Meglerstatistikk
Fant ingen data
Selskapshendelser
Vis alle
Kommende
2025 Q4-rapport
26. mars 2026
Historisk
2025 Q3-rapport
5. nov.
2025 Q2-rapport
12. aug.
2025 Q1-rapport
14. mai
2024 Q4-rapport
24. mars
2024 Q3-rapport
12. nov. 2024
Data hentes fra Quartr, FactSet
Kunder besøkte også
Vis mer informasjon
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Nyheter og Analyser
Nyheter & pressemeldinger
Analyser
12 nov. 01:40
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11 nov. 21:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
7 nov. 13:00
∙
Pressemelding
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
5 nov. 12:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
12 aug. 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
16 juni 13:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
14 mai 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
24 mars 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
12. november 2024 12:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
13. september 2024 02:34
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
11. september 2024 20:04
∙
Pressemelding
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
10. september 2024 11:00
∙
Pressemelding
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
27. august 2024 12:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
13. august 2024 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
13. mai 2024 20:10
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
24. april 2024 01:36
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
23. april 2024 20:17
∙
Pressemelding
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
22. april 2024 11:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
28. mars 2024 20:28
∙
Pressemelding
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
13. november 2023 21:05
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Relaterte produkter
Bull & Bear
2025 Q3-rapport
Kun PDF
30 dager siden
Nyheter og Analyser
Nyheter & pressemeldinger
Analyser
12 nov. 01:40
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11 nov. 21:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
7 nov. 13:00
∙
Pressemelding
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
5 nov. 12:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
12 aug. 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
16 juni 13:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
14 mai 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
24 mars 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
12. november 2024 12:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
13. september 2024 02:34
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
11. september 2024 20:04
∙
Pressemelding
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
10. september 2024 11:00
∙
Pressemelding
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
27. august 2024 12:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
13. august 2024 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
13. mai 2024 20:10
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
24. april 2024 01:36
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
23. april 2024 20:17
∙
Pressemelding
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
22. april 2024 11:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
28. mars 2024 20:28
∙
Pressemelding
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
13. november 2023 21:05
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Nasdaq
Antall
Kjøp
100
24,12
Selg
Antall
37,9
100
Siste handler
Tid
Pris
Antall
Kjøpere
Selger
-
-
-
-
-
Høy
-
VWAP
-
Lav
-
Omsetning ()
-
VWAP
-
Høy
-
Lav
-
Omsetning ()
-
Risikoinformasjon om aksjehandel
Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.
Meglerstatistikk
Fant ingen data
Kunder besøkte også
Vis mer informasjon
Selskapshendelser
Vis alle
Kommende
2025 Q4-rapport
26. mars 2026
Historisk
2025 Q3-rapport
5. nov.
2025 Q2-rapport
12. aug.
2025 Q1-rapport
14. mai
2024 Q4-rapport
24. mars
2024 Q3-rapport
12. nov. 2024
Data hentes fra Quartr, FactSet
Relaterte produkter
Bull & Bear
2025 Q3-rapport
Kun PDF
30 dager siden
Nyheter og Analyser
Nyheter & pressemeldinger
Analyser
12 nov. 01:40
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11 nov. 21:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
7 nov. 13:00
∙
Pressemelding
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
5 nov. 12:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
12 aug. 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
16 juni 13:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
14 mai 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
24 mars 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
12. november 2024 12:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
13. september 2024 02:34
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
11. september 2024 20:04
∙
Pressemelding
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
10. september 2024 11:00
∙
Pressemelding
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
27. august 2024 12:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
13. august 2024 11:00
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
13. mai 2024 20:10
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
24. april 2024 01:36
∙
Pressemelding
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
23. april 2024 20:17
∙
Pressemelding
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
22. april 2024 11:00
∙
Pressemelding
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
28. mars 2024 20:28
∙
Pressemelding
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
13. november 2023 21:05
∙
Pressemelding
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
Vis alle
Kommende
2025 Q4-rapport
26. mars 2026
Historisk
2025 Q3-rapport
5. nov.
2025 Q2-rapport
12. aug.
2025 Q1-rapport
14. mai
2024 Q4-rapport
24. mars
2024 Q3-rapport
12. nov. 2024
Data hentes fra Quartr, FactSet
Relaterte produkter
Bull & Bear
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Nasdaq
Antall
Kjøp
100
24,12
Selg
Antall
37,9
100
Siste handler
Tid
Pris
Antall
Kjøpere
Selger
-
-
-
-
-
Høy
-
VWAP
-
Lav
-
Omsetning ()
-
VWAP
-
Høy
-
Lav
-
Omsetning ()
-
Risikoinformasjon om aksjehandel
Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.